Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt
10.21608/odr.2025.380593.1052
Abstract
One of the leading causes of illness in the globe is the hepatitis C virus (HCV), especially because it can lead to chronic liver disorders. The pharmaceutical industry has undergone a radical change as a result of recent developments in green chemistry, which have introduced efficient, economical, and environmentally friendly synthesis methods. This review emphasises the use of green synthesis techniques in the creation of anti-HCV medications such as daclatasvir, ribavirin, and elbasvir. In terms of increasing yield, decreasing toxicity, and using less energy, methods including chemoenzymatic reactions, continuous-flow synthesis, and microbial biotransformation have shown remarkable results. The contributions of particular green techniques, such as Pd/C-catalyzed microwave-assisted processes and nanoparticle-based sensing systems, to the optimisation of antiviral production and development of important anti-HCV drugs with the goal of striking a balance between environmental responsibility and therapeutic efficacy are examined. These strategies highlight how important it is to combine sustainability with innovative therapeutics in the battle against HCV
Mohamed, R. (2025). Brief Review focuses on the green synthesis approaches employed in the development of key anti-HCV medications. Octahedron Drug Research, 7(1), 7-13. doi: 10.21608/odr.2025.380593.1052
MLA
Rogy Reda Mohamed. "Brief Review focuses on the green synthesis approaches employed in the development of key anti-HCV medications", Octahedron Drug Research, 7, 1, 2025, 7-13. doi: 10.21608/odr.2025.380593.1052
HARVARD
Mohamed, R. (2025). 'Brief Review focuses on the green synthesis approaches employed in the development of key anti-HCV medications', Octahedron Drug Research, 7(1), pp. 7-13. doi: 10.21608/odr.2025.380593.1052
VANCOUVER
Mohamed, R. Brief Review focuses on the green synthesis approaches employed in the development of key anti-HCV medications. Octahedron Drug Research, 2025; 7(1): 7-13. doi: 10.21608/odr.2025.380593.1052
)
View on SCiNiTO